Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Vasopressin V1a receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Oxytocin receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Vasopressin V2 receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | biogenic amine (octopamine/dopamine) receptor | Vasopressin V2 receptor | 371 aa | 382 aa | 22.5 % |
Echinococcus multilocularis | allatostatin A receptor | Oxytocin receptor | 388 aa | 311 aa | 21.9 % |
Echinococcus multilocularis | orexin receptor type 2 | Oxytocin receptor | 388 aa | 332 aa | 23.2 % |
Echinococcus granulosus | neuropeptide receptor | Oxytocin receptor | 388 aa | 324 aa | 21.9 % |
Onchocerca volvulus | Phospholipase d-related homolog | Oxytocin receptor | 388 aa | 330 aa | 20.0 % |
Echinococcus multilocularis | rhodopsin orphan GPCR | Vasopressin V1a receptor | 424 aa | 370 aa | 21.9 % |
Schistosoma mansoni | biogenic amine (5HT) receptor | Vasopressin V2 receptor | 371 aa | 357 aa | 21.6 % |
Onchocerca volvulus | Vasopressin V1a receptor | 424 aa | 378 aa | 21.4 % | |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Oxytocin receptor | 388 aa | 349 aa | 22.9 % |
Echinococcus multilocularis | neuropeptides capa receptor | Vasopressin V1a receptor | 424 aa | 462 aa | 19.5 % |
Loa Loa (eye worm) | hypothetical protein | Vasopressin V1a receptor | 424 aa | 382 aa | 22.8 % |
Echinococcus multilocularis | thyrotropin releasing hormone receptor | Vasopressin V2 receptor | 371 aa | 314 aa | 21.3 % |
Echinococcus granulosus | thyrotropin releasing hormone receptor | Vasopressin V2 receptor | 371 aa | 310 aa | 20.3 % |
Echinococcus granulosus | allatostatin A receptor | Oxytocin receptor | 388 aa | 313 aa | 23.6 % |
Onchocerca volvulus | Vasopressin V1a receptor | 424 aa | 347 aa | 21.9 % | |
Onchocerca volvulus | Vasopressin V2 receptor | 371 aa | 315 aa | 22.5 % | |
Schistosoma japonicum | ko:K04136 adrenergic receptor, alpha 1b, putative | Vasopressin V1a receptor | 424 aa | 400 aa | 21.8 % |
Echinococcus multilocularis | neuropeptide receptor | Oxytocin receptor | 388 aa | 324 aa | 21.6 % |
Brugia malayi | GnHR receptor homolog | Vasopressin V2 receptor | 371 aa | 304 aa | 22.4 % |
Onchocerca volvulus | Vasopressin V2 receptor | 371 aa | 331 aa | 21.4 % | |
Onchocerca volvulus | Mitochondrial inner membrane protein homolog | Oxytocin receptor | 388 aa | 346 aa | 24.0 % |
Schistosoma japonicum | ko:K04209 neuropeptide Y receptor, invertebrate, putative | Oxytocin receptor | 388 aa | 327 aa | 19.3 % |
Onchocerca volvulus | Oxytocin receptor | 388 aa | 327 aa | 23.9 % | |
Schistosoma japonicum | ko:K04134 cholinergic receptor, invertebrate, putative | Oxytocin receptor | 388 aa | 323 aa | 21.7 % |
Echinococcus granulosus | orexin receptor type 2 | Oxytocin receptor | 388 aa | 338 aa | 24.3 % |
Schistosoma mansoni | adenoreceptor | Vasopressin V2 receptor | 371 aa | 317 aa | 26.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | carbonic anhydrase | 0.2782 | 0.4967 | 0.4913 |
Schistosoma mansoni | carbonic anhydrase-related | 0.2782 | 0.4967 | 0.4913 |
Plasmodium falciparum | carbonic anhydrase | 0.2782 | 0.4967 | 1 |
Leishmania major | DNA topoisomerase ii | 0.0115 | 0.0084 | 0.0027 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0128 | 0.0107 | 0.0077 |
Echinococcus granulosus | carbonic anhydrase | 0.2782 | 0.4967 | 0.4913 |
Schistosoma mansoni | carbonic anhydrase II (carbonate dehydratase II) | 0.553 | 1 | 1 |
Leishmania major | carbonic anhydrase family protein, putative | 0.3224 | 0.5776 | 0.5752 |
Brugia malayi | Carbonic anhydrase like protein 2 precursor | 0.2782 | 0.4967 | 0.4913 |
Mycobacterium leprae | CARBONIC ANHYDRASE (CARBONATE DEHYDRATASE) (CARBONIC DEHYDRATASE) | 0.3224 | 0.5776 | 0.5 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0115 | 0.0084 | 0.0027 |
Trypanosoma cruzi | carbonic anhydrase-like protein, putative | 0.553 | 1 | 1 |
Echinococcus multilocularis | carbonic anhydrase | 0.2782 | 0.4967 | 0.4913 |
Echinococcus multilocularis | carbonic anhydrase | 0.2782 | 0.4967 | 0.4913 |
Trichomonas vaginalis | conserved hypothetical protein | 0.3233 | 0.5793 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0093 | 0.0043 | 0.5 |
Brugia malayi | Eukaryotic-type carbonic anhydrase family protein | 0.2782 | 0.4967 | 0.4913 |
Loa Loa (eye worm) | hypothetical protein | 0.3431 | 0.6156 | 0.6145 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0115 | 0.0084 | 0.0027 |
Brugia malayi | Eukaryotic-type carbonic anhydrase family protein | 0.2782 | 0.4967 | 0.4913 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0093 | 0.0043 | 0.5 |
Brugia malayi | Putative carbonic anhydrase 5 precursor | 0.553 | 1 | 1 |
Loa Loa (eye worm) | eukaryotic-type carbonic anhydrase | 0.553 | 1 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0069 | 0 | 0.5 |
Trypanosoma cruzi | carbonic anhydrase-like protein, putative | 0.553 | 1 | 1 |
Echinococcus granulosus | carbonic anhydrase II | 0.553 | 1 | 1 |
Echinococcus multilocularis | carbonic anhydrase II | 0.553 | 1 | 1 |
Mycobacterium ulcerans | carbonic anhydrase | 0.3233 | 0.5793 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0115 | 0.0084 | 0.0027 |
Trichomonas vaginalis | conserved hypothetical protein | 0.3233 | 0.5793 | 1 |
Schistosoma mansoni | carbonic anhydrase | 0.3224 | 0.5776 | 0.5731 |
Schistosoma mansoni | carbonic anhydrase | 0.2782 | 0.4967 | 0.4913 |
Mycobacterium tuberculosis | Beta-carbonic anhydrase | 0.2078 | 0.3678 | 1 |
Loa Loa (eye worm) | carbonic anhydrase 3 | 0.553 | 1 | 1 |
Toxoplasma gondii | hypothetical protein | 0.2782 | 0.4967 | 1 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0128 | 0.0107 | 0.0131 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0115 | 0.0084 | 0.0027 |
Trypanosoma brucei | carbonic anhydrase-like protein | 0.553 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2782 | 0.4967 | 0.4952 |
Schistosoma mansoni | carbonic anhydrase-related | 0.2782 | 0.4967 | 0.4913 |
Entamoeba histolytica | carbonic anhydrase, putative | 0.3224 | 0.5776 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0122 | 0.0097 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.2782 | 0.4967 | 0.4913 |
Leishmania major | carbonic anhydrase-like protein | 0.553 | 1 | 1 |
Brugia malayi | Carbonic anhydrase like protein 2 precursor | 0.2782 | 0.4967 | 0.4913 |
Loa Loa (eye worm) | hypothetical protein | 0.2782 | 0.4967 | 0.4952 |
Brugia malayi | Eukaryotic-type carbonic anhydrase family protein | 0.2782 | 0.4967 | 0.4913 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0093 | 0.0043 | 0.5 |
Schistosoma mansoni | carbonic anhydrase-related | 0.2782 | 0.4967 | 0.4913 |
Schistosoma mansoni | carbonic anhydrase II (carbonate dehydratase II) | 0.553 | 1 | 1 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0128 | 0.0107 | 0.5 |
Echinococcus multilocularis | carbonic anhydrase | 0.2782 | 0.4967 | 0.4913 |
Echinococcus granulosus | carbonic anhydrase | 0.2782 | 0.4967 | 0.4913 |
Loa Loa (eye worm) | eukaryotic-type carbonic anhydrase | 0.2782 | 0.4967 | 0.4952 |
Mycobacterium tuberculosis | Beta-carbonic anhydrase CanB | 0.2069 | 0.3661 | 0.9902 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.3 nM | Displacement of [3H]-OT from binding to oxytocin receptor of rat uterus | ChEMBL. | 8126695 |
IC50 (binding) | = 130 nM | Displacement of [3H]-AVP from binding to Vasopressin receptor V2 of rat kidney | ChEMBL. | 8126695 |
IC50 (binding) | = 220 nM | Displacement of [3H]-AVP from binding to arginine vasopressin 1a (V1a) column of rat liver | ChEMBL. | 8126695 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.